Switching focus back to relapsed/refractory follicular lymphoma, Sameh Gaballa, MD, and Matthew Lunning, DO, FACP, consider the list of available treatment options in this setting.
European Commission Approves Rylaze for ALL and Lymphoblastic Lymphoma
FDA Approval Insights: Talquetamab in Relapsed/Refractory Multiple Myeloma
Triplets With Azacitidine/Venetoclax Aim to Improve Responses in AML
FDA Approval Insights: Quizartinib in Newly Diagnosed, FLT3-ITD+ AML
State of the Science Summit - Hematology: Chaired by Ehab L. Atallah, MD
Oral Decitabine and Cedazuridine Wins EU Approval for Newly Diagnosed AML
Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis
Second-Line Regorafenib Demonstrates Safety in Advanced HCC, Irrespective of Prior Treatment
First-line Toripalimab Plus Sorafenib Elicits Responses in Unresectable Hepatocellular Carcinoma
Data for Luspatercept Highlight Evolving Treatment Landscape in Lower-Risk MDS